| Name | Title | Contact Details |
|---|
With roots dating back to the 1970s, we are the most experienced provider of hospice care in Michigan. Currently serving more than 1,700 patients daily, in 56 counties, we`re also the largest in our state, and among the largest recognized 501c3 non-profit advanced illness management organizations in the nation. We provide care for all—regardless of age, diagnosis, or ability to pay. Last year, our commitment extended $4 million beyond what was reimbursed by insurance. Because we welcome those who are uninsured, or whose treatment is more expensive than what other hospices can provide, we depend on the financial support of our donors for the treatments, medications, services, grief support, and spiritual care of patients and families in need.
Zotec Partners is an industry leading provider of specialized medical billing and practice management services for the hospital-based specialty market. The company is committed to the continual pursuit of excellence in the physician revenue cycle management industry by delivering effective solutions through personalized service and measurable client results. Zotec Partners` proprietary processes and technology manage in excess of 70 million medical encounters across all 50 states.
Disability Management Network is a Forest Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
St Ann's Home is a Methuen, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.